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Abstract 
PALB2 (Partner and Localizer of BRCA2) was first 
identified as a BRCA2-interacting protein. 
Subsequently, PALB2 has been recognized as a cog 
in the cellular machinery for DNA repair by 
homologous recombination (HR). PALB2 also 
mediates S and G2 DNA damage checkpoints, and 
has an apparent function in protecting 
transcriptionally active genes from genotoxic stress. 
PALB2 also interacts with, is localized by, and 
functions downstream of BRCA1. Further, PALB2 
interacts with other essential effectors of HR, 
including RAD51 and RAD51C, as well as BRCA2. 
Consistent with its function in HR and its interaction 
with key HR proteins, PALB2-deficient cells are 
hypersensitive to ionizing radiation and DNA 
interstrand crosslinking agents such as mitomycin C 
and cisplatin. Mechanistically, PALB2 is required 
for HR by mediating the recruitment of BRCA2 and 
the RAD51 recombinase to sites of DNA damage. 
Similar to bi-allelic loss-of-function mutations of 
BRCA1, BRCA2, RAD51 and RAD51C, bi-allelic 
mutations in PALB2 cause Fanconi anemia (FA), a 
rare childhood disorder which is associated with 
progressive bone marrow failure, congenital 
anomalies, and a predisposition to leukemia and 
solid tumors. Due to their close functional 
relationship, bi-allelic mutations of PALB2 and 
BRCA2 cause particularly severe forms of FA, 
called FANCN and FANCD1, both characterized by 
severe congenital abnormalities and very early onset 
of various cancers. This includes acute leukemias, 
Wilms tumor, medulloblastoma and 
neuroblastomas. Also, heterozygous germ-line 
mutations of PALB2, like mutations in several other 
essential HR genes listed above, yield an increased 
susceptibility to breast and pancreatic cancer. 
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As outlined by NCBI (Gene), coding genes most 
proximal to PALB2 on 16p12.2, in the centromeric 
to telomeric direction, are ERN2 (endoplasmic 
reticulum to nucleus signalling 2), PLK1 (polo-like 
kinase 1), DCTN5 (dynactin subunit 5), PALB2, 
NDUFAB1 (NADH:ubiquinone oxidoreductase 
subunit AB1), UBFD1  (ubiquitin family domain 
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containing 1), and EARS2 (glutamyl-tRNA 
synthetase 2). 
DNA/RNA 
The PALB2 protein was identified as a BRCA2-
interacting protein using mass spectrometry. This 
was found to correspond to gene locus 79728 
(LOC79728), which encodes putative protein 
FLJ21816 (Xia et al., 2006). In the same study, the 
first cDNA clone for human PALB2 was generated 
using RT-PCR. The human transcript includes 13 
exons arranged as diagrammed below: 
 
Exon structure of the human PALB2 gene.  Exons are delineated by a vertical black line. The coding 
sequences are shown in grey, while non-coding sequences in exons 1 and 13 are shown in white. (Above) The 
encoded protein is shown in blue with key domains and/or motifs that mediate interactions shown in black.  CC, 
coiled-coil; ChAM, chromatin association motif; LDEETGE, extended EDGE motif
. 
Description 
The human PALB2 gene (13 exons) spans 38.14 kb. 
Transcription 
Absent confirmed splice variants, the full-length 
transcript of PALB2 is 4,003 bp. 
Protein 
PALB2 has a large number of interactions with other 
DNA damage response proteins that function in 
DNA repair by homologous recombination, as 
illustrated below and reviewed elsewhere (Park et 
al., 2014b). This includes interactions with BRCA1, 
BRCA2, RAD51, RAD51C and XRCC3. In this 
way, PALB2 functions in a large network of HR 
proteins and seems to have a key role in coordinating 
their function (Park et al., 2014b). In particular, 
direct binding to BRCA1 mediates PALB2 
recruitment to DNA damage foci (Zhang et al., 
2009a; Zhang et al., 2009b). Notably, KEAP1-
dependent ubiquitination of the PALB2 coiled-coil 
domain suppresses HR in G1 by inhibiting the 
interaction of PALB2 with BRCA1 (Orthwein et al., 
2015). Importantly, direct interactions of the N- and 
C-termini of PALB2 with BRCA1 and BRCA2, 
respectively, physically links these tumor suppressor 
proteins (Sy et al., 2009b; Zhang et al., 2009a; Zhang 
et al., 2009b).  
 
PALB2 also directly interacts with MORF4L1 
(MRG15); this interaction appears to be  
 
independent of the interaction of MRG15 with the 
TIP60 histone methyltransferase complex 
(Hayakawa et al., 2010; Sy et al., 2009a). 
Additionally, PALB2 interacts with KEAP1, a 
sensor of oxidative stress (Ma et al., 2012).  
 
PALB2 is essential for embryonic development; 
homozygous knockout of PALB2 in mice disrupts 
the normal differentiation of mesoderm and results 
in embryonic lethality by E9.5 (Bowman-Colin et 
al., 2013; Rantakari et al., 2010). 
Description 
PALB2 contains a coiled-coil domain at its N-
terminus from amino acids (a.a.) 9-44, which 
mediates interaction with BRCA1 (Sy et al., 2009b; 
Zhang et al., 2009a; Zhang et al., 2009b). A nearby  
 
sequence present at a.a. 88-94 in human PALB2 is 
responsible for interaction with KEAP1 (Ma et al., 
2012). PALB2 contains a Chromatin Association 
Motif (ChAM) from a.a. 395-446 and a FXLP mofif 
from a.a. 612-615, which binds to MRG15, thereby 
promoting the interaction of PALB2 with chromatin 
(Bleuyard et al., 2012; Hayakawa et al., 2010; Xie et 
al., 2012). The C-terminal WD40 domain of PALB2, 
from a.a. 867-1186, directly binds BRCA2 (Oliver et 
al., 2009), RAD51 (Buisson et al., 2010), RAD51C 
and XRCC3 (Park et al., 2014a), POLE (pol η) 
(Buisson et al., 2014) and RNF168 (Luijsterburg et 
al., 2017). Within the WD40 domain, there is a 
hidden nuclear protein export signal from a.a. 928-
945 (Pauty et al., 2017). 
 
Key domains in the PALB2 protein and interactions they mediate.  Functional domains (or motifs) are 
shown in black and are identified above the diagram; the amino acids that each domain spans is noted in 
parentheses. Known interactions which are mediated by the particular domain or motif are shown beneath the 
diagram. 
Expression 
According to The Human Protein Atlas (online), 
PALB2 is ubiquitously expressed to varying degrees 
across different tissues including the brain, bone 
marrow, spleen, lung, liver, pancreas, stomach, 
kidney, testis, ovary and skin. 
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Localisation 
PALB2 localises to nuclei in both chromatin and the 
nucleoplasm during interphase (Xia et al., 2006). In 
untreated populations of human cancer cells, the 
majority of cells display a dispersed non-nucleolar 
signal while a subset of cells also display DNA 
damage foci. Treatment with agents that induce 
DNA damage and/or replication stress increases the 
assembly of nuclear DNA damage foci. The 
assembly of PALB2 nuclear foci requires interaction 
of the protein with BRCA1 (Zhang et al., 2009a; 
Zhang et al., 2009b). Additionally, the recruitment of 
PALB2 into foci is also promoted by MDC1, RNF8, 
UIMC1 (RAP80) and ABRAXAS1 (Abraxas), all of 
which are involved in the recruitment of BRCA1 
(Zhang et al., 2012), and by RNF168 (Luijsterburg 
et al., 2017). MRG15, PALB2 phosphorylated at S59 
and hypophosphorylated at S64, the APRIN 
cohesion factor and phosphorylated RPA2 also 
promote the recruitment of PALB2 to sites of DNA 
damage (Brough et al., 2012; Buisson et al., 2017; 
Hayakawa et al., 2010; Murphy et al., 2014). 
Function 
PALB2 acts as a typical cancer suppressor gene. 
Mono-allelic loss-of-function germline mutations 
are associated with an increased risk of developing 
breast cancer (Antoniou et al., 2014; Erkko et al., 
2007; Rahman et al., 2007) and pancreatic cancer 
(Jones et al., 2009). Bi-allelic mutations in PALB2 
(FANCN) cause a severe form of Fanconi anemia, 
subtype FA-N, with early onset of acute myeloid 
leukemia, medulloblastoma, neuroblastoma and 
often Wilms' tumor, leading to early death in the first 
decade of life (Reid et al., 2007).  
 
PALB2 is believed to act as a tumor suppressor 
protein by mediating DNA repair and thereby 
suppressing genome instability (Park et al., 2014b). 
Importantly, PALB2/FANCN-deficient cells have 
largely reduced levels of wild-type BRCA2 protein 
(Xia et al., 2007; Xia et al., 2006), reflective of a role 
for PALB2 in stabilizing the BRCA2 protein. 
Therefore, the phenotypes of these cells, as well as 
the clinical phenotypes of FA-N patients, are very 
similar to those of cells from patients with a BRCA2/ 
FANCD1 deficiency.  
 
As demonstrated by employing reporter constructs 
integrated into human cells, PALB2 has an important 
role in mediating the repair of DNA double-strand 
breaks (DSBs) by homologous recombination (HR) 
(Xia et al., 2006). While not specifically tested for 
PALB2, its partner BRCA2 has an additional role in 
mediating HR in response to DNA interstrand 
crosslinks (ICLs); ICLs are specifically repaired by 
FA proteins (Nakanishi et al., 2011). Consistent with 
a requirement for PALB2 in DNA repair by HR, and 
due to largely reduced BRCA2 protein levels, 
PALB2-deficient cells are hypersensitive to DNA 
interstrand crosslinking agents such as mitomycin C 
(MMC) and cisplatin (Xia et al., 2007; Xia et al., 
2006), and to ionizing radiation (IR) (Park et al., 
2014a). As further support for a role in DNA repair, 
PALB2-deficient cells are also hypersensitive to 
poly-ADP ribose polymerase (PARP) inhibitors 
(Buisson et al., 2010) and to aldehydes (Ghosh et al., 
2014).  
 
As a mediator of HR, PALB2 recruits BRCA2 and 
the RAD51 recombinase to sites of DNA damage 
(Xia et al., 2006). Additionally, PALB2 stabilizes 
BRCA2 present in chromatin (Xia et al., 2006). 
Biochemical experiments demonstrate that PALB2 
also directly binds DNA and promotes strand 
invasion necessary to initiate HR (Buisson et al., 
2010; Dray et al., 2010). In this process, PALB2 
decreases inhibition of D-loop formation mediated 
by RPA and enhances HR by stabilizing RAD51 
filaments. Also, PALB2 interacts with pol η, thereby 
promoting DNA synthesis at D-loops (Buisson et al., 
2014).  
 
PALB2 has additional roles in other facets of the 
DNA damage response, beyond its role in mediating 
HR. Among these, PALB2 promotes maintenance of 
G2 checkpoint arrest in response to DNA damage 
(Menzel et al., 2011). PALB2 is also required for 
chromosome stability. PALB2-deficient cells 
display increased breaks and radials in response to 
DNA damage (Bowman-Colin et al., 2013). Further, 
PALB2 has a role in protecting the cell from 
replication stress. Carriers of PALB2 mutations 
display increased firing of dormant replication 
origins (Nikkila et al., 2013) and mice with a single 
amino acid knock-in of in Brca2, p.Gly25Arg, which 
is deficient for binding to PALB2, display decreased 
fork stability in response to hydroxyurea (Hartford et 
al., 2016). Homozygosity of these Brca2 knock-in 
mice, and also hemizygosity in combination with 
Palb2 and Trp53 heterozygosity, results in defects in 
body size, fertility, meiosis and genome stability, 
and also increases tumor susceptibility (Hartford et 
al., 2016). Further, via its chromodomain, MRG15 
targets PALB2 to actively transcribed genes and 
protects them from DNA damage induced by 
camptothecin (Bleuyard et al., 2017). 
Homology 
Based on HomoloGene (NCBI), the following are 
homologs of the human PALB2 gene 
(NP_078951.2, 1186 a.a.):  
Chimpanzee (Pan troglodytes) XP_510877.2, 1186 
a.a.  
Rhesus monkey (Macaca mulatta) 
XP_001095569.2, 1135 a.a.  
Dog (Canis lupus familiaris) XP_850671.2, 1195 
a.a.  
Mouse (Mus musculus) NP_001074707.1, 1104 a.a.  
Rat (Rattus norvegicus) NP_001178532.1, 1110 a.a.  
Chicken (Gallus gallus) XP_004945321.1, 1341 a.a. 
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Mutations 
Germ-line frameshift, splice site and nonsense 
mutations that result in truncation of at least part of 
the C-terminal WD40 domain of PALB2, which 
binds BRCA2, are linked to Fanconi anemia (Reid et 
al., 2007; Xia et al., 2007), as well as breast cancer 
and pancreatic cancer (Erkko et al., 2007; Jones et 
al., 2009; Rahman et al., 2007; Tischkowitz et al., 
2007). Consistent with the role of PALB2 as an 
interaction partner in a large DNA repair network, 
these mutations disrupt the binding of PALB2 with 
BRCA2 and other partners, thereby diminishing 
DNA repair by HR.  
 
Germ-line, as well as acquired missense mutations, 
have also been reported in breast cancer patients 
(Casadei et al., 2011). At the time of writing, 2023 
distinct variations were listed in Clinvar 
(https://www.ncbi.nlm.nih.gov/clinvar/?term=palb2
%5Bgene%5D) for PALB2, with 244 frameshift, 
110 nonsense, 43 splice site, 14 near gene/UTR, and 
966 missense alterations listed. Notably, the clinical 
significance, as well as the functional significance, 
of most of these amino acid exchanges is unknown. 
These are therefore termed variants of uncertain 
significance (VUS). However, we have 
demonstrated by functional tests in reconstituted 
PALB2-deficient FA cells that the p.L939W and 
p.L1143P variants in the WD40 domain of PALB2 
decrease the efficiency of HR and confer partial 
resistance to IR, when compared to cells 
reconstituted with wild-type PALB2 (Park et al., 
2014a). More recently, it has been demonstrated that 
the c.104T>C (p.L35P) missense mutant in the N-
terminus of PALB2 segregates with malignancies in 
a family with a strong history of breast cancer (Foo 
et al., 2017). The p.L35P mutant protein completely 
abrogates the interaction of PALB2 with BRCA1 
and therefore shows no protein activity in HR assays 
or in assays of cellular resistance to platinum and 
PARP inhibitors. The findings with p.L35P 
demonstrate that missense mutations in PALB2 can 
be pathogenic. Considering the large number of 
PALB2 VUS, and given the importance of PALB2 
functionality for determining prognosis and 
treatment stratification in patients, significant efforts 
should be undertaken to systematically determine the 
functional consequences of such variants on defined 
cellular functions. Determination of the effects of 
PALB2 VUS on cellular sensitivity to PARP 
inhibitors, cisplatin and related drugs, and irradiation 
is particularly important, since PALB2 promotes 
cellular resistance to each of these therapeutic 
agents. 
Epigenetics 
Hypermethylation of CpG islands in the PALB2 
promoter has been observed in a subset of cases of 
inherited and sporadic breast cancer, and in ovarian 
cancer (Potapova et al., 2008). 
Implicated in 
Germ-line bi-allelic and heterozygous loss-of-
mutations in PALB2 are associated with different 
clinical disorders and outcomes. Bi-allelic 
inactivating mutations of PALB2 result in Fanconi 
anemia subtype N (FA-N, gene: FANCN), while 
heterozygous inheritance of a deleterious PALB2 
mutation increases the lifetime risk of developing 
breast and pancreatic cancer. Loss of heterozygosity 
has not been consistently detected in tumors that 
develop in carriers of heterozygous PALB2 
mutations (Hartley et al., 2014). How much germ-
line mutations of PALB2 increase the risk of 
developing other malignancies, such as ovarian or 
lung cancers, remains to be determined (Phuah et al., 
2013). 
Fanconi Anemia (FA) 
Just seven months after the identification and 
characterization of PALB2 as a novel BRCA2 
binding protein (Xia et al., 2006), two independent 
groups identified a total of eight FA patients with 
biallelic mutations in PALB2: [(Xia et al., 2007): 
n=1, (Reid et al., 2007): n=7]. These patients 
exhibited a severe FA phenotype with pronounced 
congenital abnormalities and a high incidence of 
malignancies before age seven that was similar to the 
phenotype described for BRCA2-deficient FANCD1 
patients (Alter et al., 2007; Hirsch et al., 2004; 
Wagner et al., 2004). Notably, these eight children 
developed 12 distinct malignancies (5X 
medulloblastoma, 3X Wilms tumors, 2X acute 
myeloid leukemia, 1X neuroblastoma and 1X 
hemangioendothelioma) before five years of age. 
One German patient experienced three different 
malignancies at 12 months of age, and there were 
cases of breast and pancreatic cancers present in the 
families (Reid et al., 2007). PALB2 was the 12th 
identified FA gene, defining the FA-N 
complementation group.  
 
At present, 22 FA or FA-like genes have been 
identified (Nepal et al., 2017). Except for the X-
linked FANCB and the autosomal dominant RAD51 
(FANCR), FA genes are autosomal recessive tumor 
suppressor genes. Based on the central activation 
step in the FA pathway, the monoubiquitination of 
the FANCD2/ FANCI protein dimer, one can 
distinguish the so-called early (or upstream) FA 
genes, FANC -A, -B, -C, -E, -F, -G, -L, -M, UBE2T 
(FANC-T) with no ubiquitination of FANCD2/I 
when mutated (Mamrak et al., 2017; Nepal et al., 
2017). In contrast, late/downstream FA genes are not 
required for monoubiquitination of FANCD2 and 
FANCI. These late genes include BRCA2 
(FANCD1), BRIP1 (FANCJ), 
FANCN/PALB2,/RAD51C (FANCO), RAD51 
(FANCR), BRCA1 (FANCS), XRCC2 (FANCU), 
MAD2L2 (FANCV/polTheta) and RFWD3 
(FANCW). Most FA patients have bi-allelic 
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mutations in the upstream FA genes, especially 
FANCA, FANCC and FANCG, and show the 
characteristic clinical features of FA. These clinical 
features include progressive bone marrow failure 
around 7.6 years of age, various congenital 
anomalies, and a predisposition to acute myeloid 
leukemia and an assortment of solid tumors that 
occur in the second and third decade of life (Kutler 
et al., 2003). Congenital anomalies observed in FA 
patients can include microcephaly, short stature, skin 
pigmentation defects, hypogonadism, and radial ray 
anomalies. A significant number of FA patients also 
experience endocrine abnormalities (Rose et al., 
2012).  
 
In contrast to other FA complementation groups, FA 
patients that harbour biallelic mutations in 
PALB2/FANCN or its partner BRCA2/FANCD1 
show clinically indistinguishable phenotypes of 
severe FA characterized by a very early onset and 
high penetrance of cancers before age seven (Reid et 
al., 2007). More than 90% of patients succumb to 
their malignancies before ten years of age. Notably, 
the spectrum of cancers found in FA patients from 
the FANCN/PALB2 and FANCD1/BRCA2 
complementation groups is different than for other 
FA complementation groups, including frequent 
occurrences of medulloblastoma, Wilms tumor, 
neuroblastoma and hepatoblastomas (Alter et al., 
2007; Tischkowitz and Xia, 2010). Bone marrow 
failure is usually not observed in FA-N patients 
(Reid et al., 2007).  
 
On a cellular level, FA including the FA-N/PALB2 
complementation group is a chromosome instability 
syndrome. Notably, FA patients are hypersensitive 
to agents which induce DNA interstrand crosslinks 
(ICLs). Specifically, cells from FA patients display 
a characteristic spontaneous and ICL-induced 
chromosome instability; this phenotype is typically 
utilized to diagnose FA (Auerbach, 2009). Recently, 
without functional testing, next generation 
sequencing based strategies have also been 
employed to diagnose FA in patients and at the same 
time identify the defective gene (De Rocco et al., 
2014). Additionally, cells from FA patients display 
accumulation in G2-M of the cell cycle in response 
to ICLs (Bogliolo and Surralles, 2015). Other 
cellular functions affected in cells with defects in the 
FA pathway include sensitivity to aldehydes and 
oxygen, excessive cytokine production, and defects 
in the spindle assembly checkpoint, autophagy, 
cellular reprograming, unwinding of quadruplex and 
triplex DNA and microsatellite instability (Bogliolo 
and Surralles, 2015). Correction of the cellular 
phenotypes by expression of the appropriate FA 
gene can be utilized to determine the FA 
complementation group (Chandra et al., 2005; 
Hanenberg et al., 2002; Virts et al., 2015). For 
patients with a deficiency for FANCA, stem cell 
gene therapy might become a new treatment option 
(Hanenberg et al., 2017). 
Breast Cancer 
Back-to-back with the identification of PALB2 as 
the 12th FA gene, Rahman et al. reported the 
identification of 10 out of 923 individuals (1.1%) 
from familial breast cancer pedigrees with mono-
allelic loss-of-function germ-line mutations in 
PALB2 (Rahman et al., 2007). A lower frequency of 
PALB2 germ-line mutation (0.5 to 1%) was found in 
patients with or without a positive family history 
(Erkko et al., 2007; Foulkes et al., 2007). Further, 
founder mutations were detected in Finland (Erkko 
et al., 2007) and Canada (Foulkes et al., 2007).  
 
The largest study to date included 311 women and 
51 men from 154 families with loss-of-function 
germ-line PALB2 mutations, of whom 229 women 
and 7 men developed breast cancer. Biostatistical 
analyses revealed that the risk of developing breast 
cancer for PALB2 mutation carriers was increased 
by a factor of 9.07 (95% CI, 5.72 to 14.39) when 
compared to the breast cancer incidence in the 
general population (Antoniou et al., 2014). The 
cumulative risk of female heterozygous PALB2 
germ-line mutation carriers to develop breast cancer 
by the age of 70 was as high as 35%. Thus, along 
with BRCA1 and BRCA2, PALB2 is among the 
genes that confer the highest breast cancer risk when 
mutated. In a recent German study of 5589 breast 
cancer patients without mutations in BRCA1/2, loss-
of-function mutations in PALB2 accounted for 
1.15% of cases and were also significantly 
associated with bilateral breast cancer occurrence 
(Hauke et al., 2018). Only 8 out of 40 patents with 
PALB2 germ-line mutations belonged to the triple 
negative breast cancer subtype (Hauke et al., 2018).  
 
Breast cancer causing mutations of PALB2 include 
established nonsense, frameshift and splice site 
mutations, which all are thought to compromise the 
role of PALB2 in cellular responses to DNA 
damage. However, it is noteworthy that almost 50% 
of the PALB2 sequence alterations listed in ClinVar 
are missense variations of unknown clinical and 
functional significance. Importantly, loss of function 
of PALB2 is synthetically lethal with radiation, 
PARP inhibitors, and cisplatin and related 
compounds. While tumors, which are driven by 
mutations in PALB2, typically have loss of function 
of PALB2, normal tissues retain a functional copy of 
this gene. As such, radiation and/or PARP inhibitors 
or platinum compounds may be particularly effective 
against tumor cells with bi-allelic PALB2 mutations.  
 
Interestingly, the relative risk for ovarian cancer was 
only increased non-significantly to 2.31 for PALB2 
mutation carriers (Antoniou et al., 2014). This is 
surprising, as the PALB2 protein physically interacts 
with the products of other ovarian cancer 
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susceptibility genes, specifically BRCA1, BRCA2 
and RAD51C (Park et al., 2014b). 
Pancreatic Cancer 
While BRCA2, which encodes a partner of the 
PALB2 protein, is the most frequently mutated gene 
in hereditary pancreatic cancer (Shindo et al., 2017; 
Zhen et al., 2015), mutation of PALB2 is also an 
important cause of this disease (Jones et al., 2009). 
To date, truncating loss-of-function germ-line 
mutations in PALB2 have been associated with the 
development of pancreatic cancer. In some pedigrees 
of families with inherited pancreatic cancer, breast 
and other cancers have also been observed (Blanco 
et al., 2013; Zhen et al., 2015). 
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